Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.

Hepatitis C virus (HCV) infection is a global health problem, and in many countries (including the U.S.), illicit drug users constitute the group at greatest risk for contracting and transmitting HCV. Drug treatment programs are therefore unique sites of opportunity for providing medical care and support for many HCV infected individuals. This paper determines subtypes of a large sample of U.S. drug-free treatment programs (N=333) according to services they provide to patients with HCV infection, and examines the organizational and aggregate patient characteristics of programs in these subtypes. A latent class analysis identified four subtypes of HCV service provision: a "Most Comprehensive Services" class (13% of the sample), a "Comprehensive Off-Site Medical Services" class (54%), a "Medical Monitoring Services" class (8%) and a "Minimal Services" class (25%). "Comprehensive" services class programs were less likely to be outpatient and private for profit than those in the other two classes. It is of concern that so many programs belong to the "Minimal Services" class, especially because some of these programs serve many injection drug users. "Minimal Services" class programs in the U.S. need to innovate services so that their HCV infected patients can get the medical and support care they need. Similar analyses in other countries can inform their policy makers about the capacity of their drug treatment programs to provide support to their HCV infected patients.

[1]  Jeroen K. Vermunt,et al.  'EM: A general program for the analysis of categorical data 1 , 1997 .

[2]  G. Dore,et al.  Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  B. Conway,et al.  Directly observed therapy for the management of HIV-infected patients in a methadone program. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  J. Sorensen,et al.  HIV/Hepatitis Prevention in Drug Abuse Treatment Programs: Guidance From Research , 2002, Science & practice perspectives.

[5]  J. Strang,et al.  Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment , 1999, BMJ.

[6]  T. Vaughn,et al.  An organizational analysis of service patterns in outpatient drug abuse treatment units , 1995 .

[7]  G. Bigelow,et al.  Providing medical care to methadone clinic patients: referral vs on-site care. , 1994, American journal of public health.

[8]  W. Lawson,et al.  Correlates of patterns of substance abuse among patients with schizophrenia. , 1993, Hospital & community psychiatry.

[9]  D. Goldberg,et al.  Establishment of a database of diagnosed HCV-infected persons in Scotland. , 2003, Communicable disease and public health.

[10]  D. D. Des Jarlais,et al.  Gaps in the drug-free and methadone treatment program response to Hepatitis C. , 2003, Journal of substance abuse treatment.

[11]  D. Baker Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. , 2003, Reviews in gastroenterological disorders.

[12]  S. Tortu,et al.  HEPATITIS C AMONG NONINJECTING DRUG USERS: A REPORT , 2001, Substance use & misuse.

[13]  M. Stein,et al.  Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. , 2001, Drug and alcohol dependence.

[14]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[15]  H. Grunze,et al.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups , 2003, Hepatology.

[16]  Mary Ellen Kitler,et al.  Global burden of disease (GBD) for hepatitis C , 2004 .

[17]  A. McCutcheon,et al.  Latent Class Analysis , 2021, Encyclopedia of Autism Spectrum Disorders.

[18]  D. D. Jarlais,et al.  A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States. , 2004, Drug and alcohol dependence.

[19]  M. Singer,et al.  Hepatitis-associated knowledge is low and risks are high among HIV-aware injection drug users in three US cities. , 2002, Addiction.

[20]  S. Neri,et al.  Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. , 2002, Clinical therapeutics.

[21]  L. Magder,et al.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.

[22]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[23]  D. Rindskopf,et al.  The value of latent class analysis in medical diagnosis. , 1986, Statistics in medicine.

[24]  M. Backmund,et al.  Treatment of hepatitis C infection in injection drug users , 2001, Hepatology.

[25]  D. D. Des Jarlais,et al.  A nationwide survey of hepatitis C services provided by drug treatment programs. , 2002, Journal of substance abuse treatment.

[26]  G. Woody,et al.  The Effects of Psychosocial Services in Substance Abuse Treatment , 1993, JAMA.

[27]  C. Horgan,et al.  Access to services in the substance abuse treatment system. Variations by facility characteristics. , 2001, Recent developments in alcoholism : an official publication of the American Medical Society on Alcoholism, the Research Society on Alcoholism, and the National Council on Alcoholism.

[28]  K. Bjøro,et al.  Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years’ Follow-Up , 2002, European Addiction Research.

[29]  S. Mauss,et al.  A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance , 2004, Hepatology.

[30]  P McElroy,et al.  An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units. , 1999, Journal of health and social behavior.

[31]  A. Copeland,et al.  Drug abuse treatment as an HIV prevention strategy: a review. , 2000, Drug and alcohol dependence.

[32]  M. Layton,et al.  Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. , 2002, American journal of public health.

[33]  J. Hoofnagle,et al.  Optimal therapy of hepatitis C , 2002, Hepatology.

[34]  A. Rosenblum,et al.  Hepatitis C and Substance Use in a Sample of Homeless People in New York City , 2001, Journal of addictive diseases.

[35]  J. Duchin,et al.  Sharing of drug preparation equipment as a risk factor for hepatitis C. , 2001, American journal of public health.

[36]  G. Dunteman,et al.  Treatment services in two national studies of community-based drug abuse treatment programs , 1995 .

[37]  S. Creech,et al.  Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse , 2003, American Journal of Gastroenterology.

[38]  D. Sylvestre Treating hepatitis C virus infection in active substance users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  S. Tortu,et al.  Sharing of Noninjection Drug-Use Implements as a Risk Factor for Hepatitis C , 2004, Substance use & misuse.

[40]  J. Sellwood,et al.  Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance. , 2003, Communicable disease and public health.

[41]  M. French,et al.  Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. , 1999, Substance use & misuse.

[42]  R. Booth,et al.  The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. , 2002, Addiction.

[43]  P. Selwyn,et al.  Utilization of on-site primary care services by HIV-seropositive and seronegative drug users in a methadone maintenance program. , 1993, Public health reports.

[44]  J. Kaldor,et al.  Epidemiology of hepatitis C virus infection in Australia. , 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[45]  Inda,et al.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. , 1999, The New England journal of medicine.

[46]  J. Hoofnagle,et al.  Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C , 2000, Annals of Internal Medicine.

[47]  D. D. Des Jarlais,et al.  Integrating hepatitis C services into existing HIV services: the experiences of a sample of U.S. drug treatment units. , 2005, AIDS patient care and STDs.

[48]  D. D. Des Jarlais,et al.  Provision of Hepatitis C Education in a Nationwide Sample of Drug Treatment Programs , 2003, Journal of drug education.

[49]  B. Edlin Prevention and treatment of hepatitis C in injection drug users , 2002, Hepatology.

[50]  H. Hagan,et al.  The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units , 2004, Journal of Urban Health.

[51]  D. Rubin,et al.  Testing the number of components in a normal mixture , 2001 .

[52]  R. Hubbard,et al.  Treatment structure and program services in the Drug Abuse Treatment Outcome Study (DATOS). , 1997 .

[53]  D. Vlahov,et al.  Correlates of Hepatitis C Virus Infections among Injection Drug Users , 1995, Medicine.